← All trials
NCT04794530
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2021
- Primary completion
- Oct 31, 2025
- Completion date
- Apr 30, 2026
- First posted
- Mar 12, 2021
- Last posted
- Oct 19, 2021
- Enrollment
- 190
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Northwestern UniversityLead sponsor
- University of ChicagoCollaborator
- Northwestern UniversityReponsible party - principal investigator
- Northwestern UniversityOverall official - principal investigator
- National Institute on Aging (NIA)Collaborator
- University of MinnesotaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.